rifampin Side Effects
Also known as: Rifadin
Analysis of 13,451 adverse event reports submitted to the FDA from 2004 to 2025.
Total Reports
13,451
Death-Related
1,383
10.3% of reports
Hospitalizations
5,402
40.2% of reports
Top Indication
Product Used For Unknown Indication
Most Reported Adverse Reactions
Who Reports Side Effects
Gender Distribution
Age Distribution
Reporting Trend by Year
Reactions in Death Reports
Top reactions reported in 1,383 reports where death was an outcome. These are voluntarily reported and do not establish causation.
| Reaction | Reports |
|---|---|
| DRUG INEFFECTIVE | 313 |
| DEATH | 185 |
| OFF LABEL USE | 124 |
| MULTIPLE ORGAN DYSFUNCTION SYNDROME | 76 |
| RESPIRATORY FAILURE | 69 |
| ACUTE KIDNEY INJURY | 63 |
| SEPSIS | 63 |
| DRUG INTERACTION | 60 |
| CONDITION AGGRAVATED | 57 |
| DRUG INEFFECTIVE FOR UNAPPROVED INDICATION | 57 |
| DYSPNOEA | 55 |
| THROMBOCYTOPENIA | 54 |
| GENERAL PHYSICAL HEALTH DETERIORATION | 53 |
| NAUSEA | 51 |
| DRUG-INDUCED LIVER INJURY | 50 |
| PNEUMONIA | 50 |
| TREATMENT FAILURE | 50 |
| DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS | 49 |
| SEPTIC SHOCK | 49 |
| CARDIAC ARREST | 46 |
Reactions in Hospitalization Reports
Top reactions in 5,402 reports where hospitalization was an outcome.
| Reaction | Reports |
|---|---|
| DRUG INEFFECTIVE | 616 |
| DRUG INTERACTION | 482 |
| OFF LABEL USE | 416 |
| DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS | 404 |
| PYREXIA | 336 |
| NAUSEA | 282 |
| ACUTE KIDNEY INJURY | 266 |
| VOMITING | 239 |
| CONDITION AGGRAVATED | 228 |
| DIARRHOEA | 185 |
| DYSPNOEA | 178 |
| RASH | 178 |
| PARADOXICAL DRUG REACTION | 162 |
| THROMBOCYTOPENIA | 154 |
| DRUG-INDUCED LIVER INJURY | 143 |
| PNEUMONIA | 135 |
| COUGH | 131 |
| EOSINOPHILIA | 131 |
| ASTHENIA | 129 |
| FATIGUE | 121 |
Nearby — Related Medications
What the FAERS Data Reveals About rifampin Side Effects
The FDA Adverse Event Reporting System (FAERS) contains 13,451 voluntary reports linked to rifampin and its brand equivalents (Rifadin), spanning 2004 through 2025. Of those, 1,383 (10.3%) listed death as an outcome and 5,402 (40.2%) involved hospitalization. The most common indication reported alongside adverse events was Product Used For Unknown Indication.
Demographic breakdowns help contextualize who is being exposed to the drug. Of reports with known sex, 50% were female and 50% male; age distribution skews toward 18-44, with 2,935 reports in that bracket. The single most reported reaction is drug ineffective with 1,468 submissions, followed by off label use and drug interaction.
FAERS is a signal-detection tool, not a scorecard. Reports are voluntary, and a single case may list multiple suspect drugs, so numbers above should not be read as incidence rates or per-patient risk. Widely prescribed drugs naturally accumulate more reports than niche therapies even when individual risk is low. These aggregates are useful for spotting patterns that merit further pharmacovigilance, not for choosing between medications. This page is for educational reference only and is not medical advice — speak with a licensed clinician about any side-effect concerns.
Read our methodology — how this data is sourced, computed, and verified.